Real‐world benefit of combination palbociclib and endocrine therapy for metastatic breast cancer and correlation with neutropenia

BACKGROUND: Combination CDK4/6 inhibitor and endocrine therapy has been shown to significantly improve progression‐free survival (PFS) in patients with hormone receptor (HR)‐positive, HER2‐negative metastatic breast cancer (mBC). The aim of this retrospective study was to evaluate the real‐world ben...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, James, Zhong, Xiaojun, Ma, Junjie, Sun, Weihong, Han, Hyo S., Soliman, Hatem H., Loftus, Loretta S., Costa, Ricardo L. B., Armaghani, Avan J., Soyano‐Muller, Aixa E., Czerniecki, Brian J., Lee, M. Catherine, Kiluk, John V., Khakpour, Nazanin, Hoover, Susan J., Laronga, Christine, Khong, Hung T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8559460/
https://www.ncbi.nlm.nih.gov/pubmed/34590788
http://dx.doi.org/10.1002/cam4.4295

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8559460/
https://www.ncbi.nlm.nih.gov/pubmed/34590788
http://dx.doi.org/10.1002/cam4.4295

Ejemplares similares